Pharmabiz

Ipsen receives CHMP’s positive opinion on Ojemda for treating monotherapy of children with relapsed or refractory BRAF-altered paediatric low-grade glioma

Ipsen receives CHMP’s positive opinion on Ojemda for treating monotherapy of children with relapsed or refractory BRAF-altered paediatric low-grade glioma: Paris Wednesday, Marc ...
Pharmabiz

Roche announces FENhance 1 phase III study of fenebrutinib for relapsing and primary progressive MS meets its primary endpoint

Roche announces FENhance 1 phase III study of fenebrutinib for relapsing and primary progressive MS meets its primary endpoint: Basel Wednesday, March 4, 2026, 14:00 Hrs [IST] Roc ...
Pharmabiz

Regeneron-Sanofi’s Dupixent recommended by CHMP for EU approval to treat CSU in young children with ongoing symptoms despite treatment

Tarrytown, New York Wednesday, March 4, 2026, 13:00 Hrs [IST] ...
Pharmabiz

EMA recommends marketing authorisation to Norgine’s mavorixafor in patients aged 12 years and older to treat of WHIM syndrome

EMA recommends marketing authorisation to Norgine’s mavorixafor in patients aged 12 years and older to treat of WHIM syndrome: Amsterdam Wednesday, March 4, 2026, 12:00 Hrs [IST ...
Pharmabiz

Practo appoints Cijo George as vice president of AI as the company scales its outcome-driven healthcare platform globally

Practo appoints Cijo George as vice president of AI as the company scales its outcome-driven healthcare platform globally: Our Bureau, Bengaluru Wednesday, March 4, 2026, 12:15 Hr ...
Pharmabiz

Philips and ACTREC Tata Memorial Cancer Centre to strengthen early cancer detection in India with Spectral CT

Philips and ACTREC Tata Memorial Cancer Centre to strengthen early cancer detection in India with Spectral CT: Our Bureau, Bengaluru Wednesday, March 4, 2026, 11:30 Hrs [IST] Phil ...
Pharmabiz

Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium

Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...
Pharmabiz

US FDA accepts Takeda and Protagonist’s NDA and grants priority review status for rusfertide as a potential first-in-class therapy for polycythaemia vera

US FDA accepts Takeda and Protagonist’s NDA and grants priority review status for rusfertide as a potential first-in-class therapy for polycythaemia vera: Osaka Wednesday, March ...
Pharmabiz

INTERPHEX WEEK TOKYO 2026 to be held from May 20–22 at Makuhari Messe

INTERPHEX WEEK TOKYO 2026 to be held from May 20–22 at Makuhari Messe: Our Bureau, Mumbai Wednesday, March 4, 2026, 09:00 Hrs [IST] INTERPHEX WEEK TOKYO 2026, one of Japan’s l ...
Opinion
PharmabizOpinion

KPRDO demands pan-India implementation of COA on drug purchases by wholesalers from pharma manufacturers

KPRDO demands pan-India implementation of COA on drug purchases by wholesalers from pharma manufacturers: Nandita Vijayasimha, Bengaluru Wednesday, March 4, 2026, 08:00 Hrs [IST] ...
Pharmabiz

CDSCO to replace SUGAM Portal with new digital platform to boost regulatory system digitisation

CDSCO to replace SUGAM Portal with new digital platform to boost regulatory system digitisation: Shardul Nautiyal, Mumbai Wednesday, March 4, 2026, 08:00 Hrs [IST] In a significan ...
Pharmabiz

BDCDA proposes K-DTTP to monitor medicines at first point of entry

BDCDA proposes K-DTTP to monitor medicines at first point of entry: Nandita Vijayasimha, Bengaluru Wednesday, March 4, 2026, 08:00 Hrs [IST] The Bangalore District Chemists and Dr ...